Gepotidacin manufacturers
- Gepotidacin
-
- $10.00 / 1ASSAYS
-
2025-11-02
- CAS:1075236-89-3
- Min. Order: 1ASSAYS
- Purity: 99%
- Supply Ability: 1 ton
- Gepotidacin
-
- $364.00 / 5mg
-
2025-10-27
- CAS:1075236-89-3
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| | Gepotidacin Basic information |
| Product Name: | Gepotidacin | | Synonyms: | Gepotidacin;Buagafuran;GSK-2140944;Gepotidacin (GSK2140944);3H,8H-2a,5,8a-Triazaacenaphthylene-3,8-dione, 2-[[4-[[(3,4-dihydro-2H-pyrano[2,3-c]pyridin-6-yl)methyl]amino]-1-piperidinyl]methyl]-1,2-dihydro-, (2R)-;(R)-2-((4-(((3,4-dihydro-2H-pyrano[2,3-c]pyridin-6-yl)methyl)amino)piperidin-1-yl)methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione;(R)-2-((4-(((3,4-Dihydro-2H-pyrano[2,3-c]pyridin-6-yl)methyl)amino)piperidin-1-yl)methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione , Gepotidacin | | CAS: | 1075236-89-3 | | MF: | C24H28N6O3 | | MW: | 448.52 | | EINECS: | 202-303-5 | | Product Categories: | | | Mol File: | 1075236-89-3.mol |  |
| | Gepotidacin Chemical Properties |
| Boiling point | 661.9±65.0 °C(Predicted) | | density | 1.52±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : 7.14 mg/mL (15.92 mM) | | form | Solid | | pka | 7.88±0.10(Predicted) | | color | White to yellow | | InChIKey | PZFAZQUREQIODZ-LJQANCHMSA-N | | SMILES | C1N2C3=C(C=CC2=O)N=CC(=O)N3[C@@H]1CN1CCC(NCC2N=CC3OCCCC=3C=2)CC1 |
| | Gepotidacin Usage And Synthesis |
| Uses | Gepotidacin (GSK2140944) is a novel triazaacenaphthylene bacterial type II topoisomerase inhibitor. | | in vivo | GSK2140944 MICs are 0.125 to 0.5 mg/L against the six MRSA isolates. ELF penetration ratios range from 1.1 to 1.4. Observed maximal decreases are 1.1 to 3.1 log10 CFU in neutropenic mice. The mean fAUC/MIC ratios required for stasis and 1-log-unit decreases are 59.3 ± 34.6 and 148.4 ± 83.3, respectively. | | References | [1] Farrell DJ, et al. In Vitro Activity of Gepotidacin (GSK2140944) against Neisseria gonorrhoeae. Antimicrob Agents Chemother. 2017 Feb 23;61(3). DOI:10.1128/AAC.02047-16
[2] Biedenbach DJ, et al. In Vitro Activity of Gepotidacin, a Novel Triazaacenaphthylene Bacterial Topoisomerase Inhibitor, against a Broad Spectrum of Bacterial Pathogens. Antimicrob Agents Chemother. 2016 Jan 4;60(3):1918-23. DOI:10.1128/AAC.02820-15
[3] O'Riordan W, et al. Efficacy, Safety, and Tolerability of Gepotidacin (GSK2140944) in the Treatment of Patients with Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections. Antimicrob Agents Chemother. 2017 May 24;61(6). DOI:10.1128/AAC.02095-16
[4] So W, et al. Pharmacodynamic Profile of GSK2140944 against Methicillin-Resistant Staphylococcus aureus in a Murine Lung Infection Model. Antimicrob Agents Chemother. 2015 Aug;59(8):4956-61. DOI:10.1128/AAC.00625-15 |
| | Gepotidacin Preparation Products And Raw materials |
| Raw materials | 1,3-Propanediol, 2-[(6-methoxy-3-nitro-2-pyridinyl)amino]--->3,4-dihydro-2H-pyrano[2,3-c]pyridine-6-carbaldehyde-->beta-lactamase-IN-1-->4-(2,2-Dimethyl-1,3-Dioxan-5-Yl)-6-Methoxypyrido[2,3-B]Pyrazin-3(4H)-One(WXC01734)-->N-(2,2-Dimethyl-1,3-Dioxan-5-Yl)-6-Methoxy-3-Nitropyridin-2-Amine-->N2-(2,2-Dimethyl-1,3-Dioxan-5-Yl)-6-Methoxypyridine-2,3-Diamine-->2-Chloro-6-methoxy-3-nitropyridine |
|